Abiopharma

🔍 Lee Sung (Executive)

Company: Tango Therapeutics, Inc. (TNGX)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 60,000 shares of Stock Option (Right to Buy) at $8.93 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: false | shares_owned_after: 60,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
• F2: This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.